Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
AIRS vs DBVT vs ALKS vs SKIN vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Household & Personal Products
Drug Manufacturers - Specialty & Generic
AIRS vs DBVT vs ALKS vs SKIN vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Biotechnology | Household & Personal Products | Drug Manufacturers - Specialty & Generic |
| Market Cap | $216M | $1712.35T | $5.90B | $118M | $1.61B |
| Revenue (TTM) | $158M | $0.00 | $1.56B | $296M | $4.18B |
| Net Income (TTM) | $-18M | $-168M | $153M | $-6M | $-1.82B |
| Gross Margin | 64.0% | — | 65.4% | 64.9% | 34.2% |
| Operating Margin | -9.3% | — | 12.3% | -3.6% | -4.1% |
| Forward P/E | — | — | 24.8x | — | 5.6x |
| Total Debt | $105M | $22M | $70M | $379M | $3.97B |
| Cash & Equiv. | $8M | $194M | $1.12B | $233M | $532M |
AIRS vs DBVT vs ALKS vs SKIN vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| AirSculpt Technolog… (AIRS) | 100 | 21.8 | -78.2% |
| DBV Technologies S.… (DBVT) | 100 | 66.0 | -34.0% |
| Alkermes plc (ALKS) | 100 | 116.9 | +16.9% |
| The Beauty Health C… (SKIN) | 100 | 3.3 | -96.7% |
| Perrigo Company plc (PRGO) | 100 | 26.0 | -74.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AIRS vs DBVT vs ALKS vs SKIN vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AIRS lags the leaders in this set but could rank higher in a more targeted comparison.
DBVT ranks third and is worth considering specifically for momentum.
- +110.4% vs PRGO's -51.2%
ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- -11.0% 10Y total return vs PRGO's -77.7%
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs PRGO's -43.5%
Among these 5 stocks, SKIN doesn't own a clear edge in any measured category.
PRGO is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Beta 1.18, yield 9.8%, current ratio 2.76x
- -2.8% revenue growth vs DBVT's -100.0%
- Lower P/E (5.6x vs 24.8x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -2.8% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (5.6x vs 24.8x) | |
| Quality / Margins | 9.8% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 1.06 vs AIRS's 3.37, lower leverage | |
| Dividends | 9.8% yield, 10-year raise streak, vs AIRS's 0.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs PRGO's -51.2% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
AIRS vs DBVT vs ALKS vs SKIN vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AIRS vs DBVT vs ALKS vs SKIN vs PRGO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 3 of 6 categories
PRGO leads 2 • DBVT leads 1 • AIRS leads 0 • SKIN leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO and DBVT operate at a comparable scale, with $4.2B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $158M | $0 | $1.6B | $296M | $4.2B |
| EBITDAEarnings before interest/tax | -$2M | -$112M | $212M | $9M | $58M |
| Net IncomeAfter-tax profit | -$18M | -$168M | $153M | -$6M | -$1.8B |
| Free Cash FlowCash after capex | $2M | -$151M | $392M | $29M | $108M |
| Gross MarginGross profit ÷ Revenue | +64.0% | — | +65.4% | +64.9% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -9.3% | — | +12.3% | -3.6% | -4.1% |
| Net MarginNet income ÷ Revenue | -11.4% | — | +9.8% | -2.0% | -43.5% |
| FCF MarginFCF ÷ Revenue | +1.6% | — | +25.1% | +9.8% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -17.8% | — | +28.2% | -6.7% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -50.0% | +91.5% | -4.1% | +38.0% | -56.4% |
Valuation Metrics
PRGO leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $216M | $1712.35T | $5.9B | $118M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $313M | $1712.35T | $4.9B | $264M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -24.71x | -0.76x | 24.76x | -5.69x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 31.06x | — | 17.25x | 7331.15x | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 1.20x | — | 4.00x | 0.39x | 0.38x |
| Price / BookPrice ÷ Book value/share | 2.52x | 0.66x | 3.28x | 2.02x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.28x | 3.17x | 11.12x |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs AIRS's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.8% | -130.2% | +8.8% | -9.4% | -50.7% |
| ROA (TTM)Return on assets | -9.0% | -89.0% | +5.4% | -1.2% | -19.8% |
| ROICReturn on invested capital | -0.8% | — | +18.9% | -6.8% | +3.7% |
| ROCEReturn on capital employed | -1.0% | -145.7% | +14.2% | -4.5% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 7 | 7 | 4 |
| Debt / EquityFinancial leverage | 1.32x | 0.13x | 0.04x | 6.20x | 1.35x |
| Net DebtTotal debt minus cash | $97M | -$172M | -$1.0B | $146M | $3.4B |
| Cash & Equiv.Liquid assets | $8M | $194M | $1.1B | $233M | $532M |
| Total DebtShort + long-term debt | $105M | $22M | $70M | $379M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -1.82x | -189.82x | 32.30x | 0.81x | -7.20x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, DBVT leads with a +110.4% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +87.0% | +4.9% | +25.3% | -35.0% | -13.5% |
| 1-Year ReturnPast 12 months | +35.2% | +110.4% | +16.5% | -35.9% | -51.2% |
| 3-Year ReturnCumulative with dividends | -34.0% | +19.7% | +14.5% | -91.7% | -58.1% |
| 5-Year ReturnCumulative with dividends | -75.6% | -69.1% | +60.9% | -92.9% | -60.1% |
| 10-Year ReturnCumulative with dividends | -75.6% | -87.0% | -11.0% | -91.6% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -12.9% | +6.2% | +4.6% | -56.4% | -25.2% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than AIRS's 3.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs AIRS's 28.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.37x | 1.26x | 1.06x | 2.00x | 1.18x |
| 52-Week HighHighest price in past year | $12.00 | $26.18 | $36.60 | $2.69 | $28.44 |
| 52-Week LowLowest price in past year | $1.51 | $7.53 | $25.17 | $0.76 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +28.8% | +76.3% | +96.7% | +33.8% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 70.0 | 48.1 | 60.2 | 52.1 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 252K | 2.3M | 760K | 3.4M |
Analyst Outlook
PRGO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: AIRS as "Hold", DBVT as "Buy", ALKS as "Buy", SKIN as "Hold", PRGO as "Hold". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44). For income investors, PRGO offers the higher dividend yield at 9.81% vs AIRS's 0.13%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $6.00 | $46.33 | $44.00 | $1.30 | $20.00 |
| # AnalystsCovering analysts | 5 | 15 | 28 | 13 | 36 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | 0 | 0 | 0 | — | 10 |
| Dividend / ShareAnnual DPS | $0.00 | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | 0.0% | +0.5% | 0.0% | 0.0% |
ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook).
AIRS vs DBVT vs ALKS vs SKIN vs PRGO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is AIRS or DBVT or ALKS or SKIN or PRGO a better buy right now?
For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.
8% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIRS or DBVT or ALKS or SKIN or PRGO?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIRS or DBVT or ALKS or SKIN or PRGO?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
06β versus AirSculpt Technologies, Inc. 's 3. 37β — meaning AIRS is approximately 218% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — AIRS or DBVT or ALKS or SKIN or PRGO?
By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.
8% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, AIRS leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AIRS or DBVT or ALKS or SKIN or PRGO?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AIRS or DBVT or ALKS or SKIN or PRGO more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
07Which pays a better dividend — AIRS or DBVT or ALKS or SKIN or PRGO?
In this comparison, PRGO (9.
8% yield), AIRS (0. 1% yield) pay a dividend. DBVT, ALKS, SKIN do not pay a meaningful dividend and should not be held primarily for income.
08Is AIRS or DBVT or ALKS or SKIN or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AIRS and DBVT and ALKS and SKIN and PRGO?
These companies operate in different sectors (AIRS (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and SKIN (Consumer Defensive) and PRGO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: AIRS is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while AIRS, DBVT, ALKS, SKIN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.